
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is a strong investment opportunity due to its positive clinical data, potential for CGM adoption, and a well-developed product pipeline. Recent studies and results have shown the clinical effectiveness and potential market expansion of CGM use, leading to a Buy rating and lowered price target of $80 from analysts. The company's focus on expanding CGM adoption and strong financial performance, with expected revenue and EPS growth, make it a promising stock for investors seeking growth in the healthcare sector.
Bears say
DexCom is facing several key risks including potential pricing pressures, competition, and high levels of investment needed to compete effectively in the diabetes device sector. However, the company has shown strong margins, with adjusted gross margin and adjusted operating margin beating expectations and adjusted EBITDA margin outperforming TD Cowen's and consensus targets. Additionally, the company has a strong cash position and is actively pursuing Medicare coverage for its technology, which could provide a significant boost to its market success and potential market opportunity in the near future. Despite these positives, the lack of traditional and/or more mature financial metrics makes it difficult to assign a specific price target.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares